BioSpace News Archive

Aligos Therapeutics, Inc. (Nasdaq: ALGS) today announced that the company is delivering several oral and poster presentations at the 32nd Conference of the Asian Pacific Association for the Study of the Liver (APASL), being held Feb 15 – 19 in Taipei, Taiwan at the Taipei International Convention Center.

The Terasaki Institute for Biomedical Innovation is proud to announce the final agenda for its Terasaki Innovation Summit, taking place on March 8th - 10th at the UCLA Meyer & Renee Luskin Center.

VolitionRx Limited, a multi-national epigenetics company, announces its Nu.Q® Vet Cancer Test is now available for pre-order to veterinarians at the point-of-care through Heska Corporation .

Convergent Therapeutics Inc. announced the titles of posters evaluating its lead asset, CONV01-α (225Ac−J591), a prostate-specific membrane antigen (PSMA)-targeted monoclonal antibody linked to Ac-225 (225Ac), that will be presented at the 2023 American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium happening in a hybrid mode at San Francisco, February 16-18.

The Janssen Pharmaceutical Companies of Johnson & Johnson announced updated results from the Phase 3 MAGNITUDE study evaluating the investigational use of niraparib, a highly selective poly polymerase inhibitor, in combination with abiraterone acetate plus prednisone in patients with metastatic castration-resistant prostate cancer with or without specific homologous recombination repair gene alterations, including BRCA mutations.

INOVIO (NASDAQ: INO) today announced positive preliminary results from the second cohort of its Phase 1/2 clinical trial evaluating INO-3107 for the treatment of HPV 6 and HPV 11-associated Recurrent Respiratory Papillomatosis (RRP) in adults.

Incyte announced that it will present at the Cowen 43rd Annual Health Care Conference on Monday, March 6, 2023 at 11:10 a.m. in Boston.

Natera, Inc. announced that it has received written confirmation from the Centers for Medicare & Medicaid Services’ Molecular Diagnostics Services Program that Natera’s Signatera molecular residual disease test has met coverage requirements for adjuvant and recurrence monitoring in patients with stage IIb or higher breast cancer.

Nemaura Medical, Inc. announces that CEO Dr. Faz Chowdhury will participate in a fireside chat at the MicroCap Rodeo Winter Wonderland Best Ideas 2023 Conference that is being held virtually on February 21 – 24, 2023.

RedHill Biopharma Ltd. today announced that following a positive pre-MAA meeting it plans to submit a Marketing Authorisation Application (MAA) to the UK Medicines & Healthcare products Regulatory Agency (MHRA) seeking approval for RHB-102 (Bekinda)[i] for oncology support (management of nausea and vomiting induced by cytotoxic chemotherapy and radiotherapy.